Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JANX007 |
Synonyms | |
Therapy Description |
JANX007 is a trispecific tumor-associated T-cell engager containing binding domains for PSMA, CD3, and albumin, as well as a CD3 inhibitory peptide mask, which potentially leads to enhanced antitumor immune response (Journal for ImmunoTherapy of Cancer 2022;10). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JANX007 | JANX-007|JANX 007 | JANX007 is a trispecific tumor-associated T-cell engager containing binding domains for PSMA, CD3, and albumin, as well as a CD3 inhibitory peptide mask, which potentially leads to enhanced antitumor immune response (Journal for ImmunoTherapy of Cancer 2022;10). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05519449 | Phase I | JANX007 | Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) | Recruiting | USA | AUS | 0 |